6XB2 Stock Overview A clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Biophytis S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Biophytis Historical stock prices Current Share Price €8.96 52 Week High €36.00 52 Week Low €0.40 Beta 1.11 1 Month Change 0% 3 Month Change -8.94% 1 Year Change n/a 3 Year Change -99.69% 5 Year Change n/a Change since IPO -99.84%
Recent News & Updates
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity Jul 11
Biophytis S.A., Annual General Meeting, Jun 24, 2024 May 17
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity May 15
Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index Apr 27
Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity Apr 19
Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone) Apr 09 See more updates
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity Jul 11
Biophytis S.A., Annual General Meeting, Jun 24, 2024 May 17
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity May 15
Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index Apr 27
Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity Apr 19
Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone) Apr 09
Biophytis S.A., Annual General Meeting, Mar 18, 2024 Feb 15
Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet Jan 06
Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases Dec 07
Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board Nov 29
Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel Oct 28
Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months Sep 29
Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19 Sep 21
Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19 Sep 20
Biophytis S.A. Announces Executive Changes Sep 14
Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia Sep 12 Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project Aug 17
Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe Aug 09
Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 Jul 23
Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound Jul 21
Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia Jul 11
Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress Jun 20
Biophytis S.A., Annual General Meeting, Jun 16, 2023 May 19
Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million. May 12
Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe May 10
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19 Feb 02
Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd Jan 20
Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice Jan 13
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19 Nov 03 Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement Oct 27
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd Sep 14
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd Sep 13 Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure Sep 07
Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit Jul 06
Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress Jun 29
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease Jun 17
Biophytis SA, Annual General Meeting, Jun 03, 2022 Apr 20
Biophytis SA Announces Chief Financial Officer Changes Apr 06
Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program Feb 04
Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3 Dec 19
Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference Oct 01
Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19 Sep 16
Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19 Aug 16
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021 Jul 14
Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021 Jul 03
Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Jul 02
BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis May 12
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021 Apr 26
Biophytis SA, Annual General Meeting, Apr 26, 2021 Mar 11
Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos Feb 18 Shareholder Returns 6XB2 DE Biotechs DE Market 7D 0% 1.9% 1.4% 1Y n/a -9.8% 9.1%
See full shareholder returns
Return vs Market: Insufficient data to determine how 6XB2 performed against the German Market .
Price Volatility Is 6XB2's price volatile compared to industry and market? 6XB2 volatility 6XB2 Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6XB2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6XB2's volatility change over the past year.
About the Company Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19.
Show more Biophytis S.A. Fundamentals Summary How do Biophytis's earnings and revenue compare to its market cap? 6XB2 fundamental statistics Market cap €2.85m Earnings (TTM ) -€17.03m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6XB2 income statement (TTM ) Revenue €0 Cost of Revenue €0 Gross Profit €0 Other Expenses €17.03m Earnings -€17.03m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -3.24 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -207.8%
How did 6XB2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/07/20 12:37 End of Day Share Price 2024/04/22 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Biophytis S.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju H.C. Wainwright & Co. Thomas Guillot Kepler Cheuvreux
Show 0 more analysts 